Dual GLP-1/Glucagon Receptor Agonist | Advanced Weight Loss & Metabolic Research | For Research Use Only

Survodutide is a powerful investigational dual receptor agonist, acting on both GLP-1 (glucagon-like peptide-1) and glucagon receptors. Originally developed by Boehringer Ingelheim and Zealand Pharma, Survodutide has gained attention for its potent effects on body weight reduction, lipid metabolism, and insulin regulation — offering promising advantages over traditional GLP-1 agonists.

This compound is at the forefront of cutting-edge metabolic research, showing rapid fat loss potential with preservation of lean mass, enhanced thermogenesis, and improved cardiometabolic markers.

🔍 Key Features

• Dual Agonist: GLP-1 + Glucagon Receptors

• Reduces Appetite While Increasing Energy Expenditure

• Improves Glucose Control & Insulin Sensitivity

• Supports Liver Health and Reduces Visceral Fat

• Ideal for Advanced Obesity & NAFLD Research

⚙️ Peptide Details

• Peptide Name: Survodutide (BI 456906)

• CAS Number: 2754576-16-4

• Molecular Formula: Proprietary complex peptide

• Molecular Weight: High molecular weight (exact value undisclosed)

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised white/off-white powder

• Unit Size: 10mg per vial

🧊 Storage & Handling

• Storage (lyophilised): Store at –20°C, away from light and moisture

• Reconstitution: Use sterile bacteriostatic water or saline

• Post-Reconstitution: Store at 2–8°C and use within 7–10 days

• Avoid: Repeated freeze-thaw cycles and exposure to air or light

⚠️ For Research Use Only

Survodutide – 10mg is provided exclusively for scientific research purposes. It is not intended for human consumption or therapeutic use. Use only in a controlled laboratory environment by qualified personnel.